A detailed history of Spire Wealth Management transactions in Exact Sciences Corp stock. As of the latest transaction made, Spire Wealth Management holds 69 shares of EXAS stock, worth $2,978. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69
Previous 161 57.14%
Holding current value
$2,978
Previous $11,000 63.64%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

SELL
$56.27 - $73.77 $5,176 - $6,786
-92 Reduced 57.14%
69 $4,000
Q4 2023

Feb 06, 2024

SELL
$59.06 - $75.72 $235,708 - $302,198
-3,991 Reduced 96.12%
161 $11,000
Q3 2023

Nov 08, 2023

BUY
$65.94 - $99.04 $46,619 - $70,021
707 Added 20.52%
4,152 $283,000
Q2 2023

Aug 09, 2023

BUY
$62.68 - $95.05 $182,273 - $276,405
2,908 Added 541.53%
3,445 $323,000
Q1 2023

May 09, 2023

BUY
$47.19 - $70.77 $5,568 - $8,350
118 Added 28.16%
537 $36,000
Q4 2022

Feb 03, 2023

BUY
$30.35 - $53.15 $9,378 - $16,423
309 Added 280.91%
419 $21,000
Q3 2022

Nov 07, 2022

SELL
$31.97 - $49.37 $12,116 - $18,711
-379 Reduced 77.51%
110 $4,000
Q2 2022

Jul 22, 2022

SELL
$35.61 - $76.23 $85,036 - $182,037
-2,388 Reduced 83.0%
489 $19,000
Q1 2022

Apr 18, 2022

SELL
$57.56 - $82.54 $184,364 - $264,375
-3,203 Reduced 52.68%
2,877 $201,000
Q4 2021

Jan 14, 2022

BUY
$72.5 - $100.68 $243,020 - $337,479
3,352 Added 122.87%
6,080 $473,000
Q3 2021

Oct 22, 2021

BUY
$90.24 - $124.05 $21,116 - $29,027
234 Added 9.38%
2,728 $260,000
Q2 2021

Jul 26, 2021

SELL
$93.66 - $139.27 $303,926 - $451,931
-3,245 Reduced 56.54%
2,494 $310,000
Q1 2021

May 21, 2021

BUY
$116.57 - $155.01 $668,995 - $889,602
5,739 New
5,739 $737,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $7.64B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Spire Wealth Management Portfolio

Follow Spire Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Spire Wealth Management with notifications on news.